Short title: Physiology and pathophysiology of Antimüllerian hormone Summary The main characteristics of the Antimüllerian hormone from the points of view of biochemistry, molecular genetics, physiological functions and importance for diagnostics in reproductive endocrinology and related biomedical fields are reviewed. The role of the hormone in male and female development, its participation in oocyte maturation including selection of a dominant follicle are summarized, as well as its changes under various pathological situations in both sexes. The physiological changes of serum AMH leves in the life span in both sexes and their alterations unde various pathological conditions are provided, too.
Introduction
The first mention about the antimüllerian hormone (AMH) is dated to 1940, when A.Jost pointed to a protein substance, formed in testes of mammals including man and different from testosterone, responsible for regression of Müllerian ducts. It was named "Müllerian Inhibiting Substance". It lasted almost 40 years before the protein was isolated and characterized, including the gene which coded for it. Soon after its receptors were described (La Marca and Volpe 2006).
As we show below, AMH is formed also in women, and measurable levels occur in blood of both sexes. Among physicians it is mostly familiar as a predictor for successful in vitro fertilization, but its examination has a wider utilization.
AMH-description
Antimüllerian hormone is a peptide belonging to the family of TGF-beta growth factors, the unique effect of which in males is a regression of Müllerian ducts during embryonal development, leading to initiation of a further dvelopment towards the male phenotype. In males it is synthesized in Sertoli cells of the testes since the 5th week of the embryonal development and then during the whole life. It is also formed in females in ovaries from the 36th week of gestation. During the female life until menopause it is exprimed in granulosa cells of small growing follicles (primary and preantral). On the other hand it is not formed in FSH-dependent (antral) follicles and also in atretic follicles The hormone passes in the blood and its levels can be measured.
From the chemical point of view AMH is a peptide homodimer of molecular weight 140 kDa, consisting of two identical glycoprotein subunits, connected by disulfide bridges. The gene for human AMH is localized on the short arm chromosome 19 and is composed from 2750 nucletide bases. The fifth exon from the 3´end codes for a biologically active part of the molecule, rich of glycine. Target organs for AMH in males are Müllerian ducts, and in both sexes gonads. The receptors for AMH are transmembrane heteromeric proteins, composed from two subunits, denoted Type I and II. As all the receptors for growth factors of the TGF-beta family, they do not use G-proteins and possess intrinsic kinase activity. Type II (better subunit) binds specifically the ligand leading thus to activation of the Type I, the intracellular part of which acts as threonin kinase. Activation of the latter starts a signal cascade resulting in a respective biological response. The gene encoding fo! r AMH receptor is composed from 11 exons more than 8 kbp in lenght and is localized on chromosome 12 (La Marca and Volpe 2006) . Soon after mapping of the genes for AMH and its receptor, their mutations were also described (Picard and Belville 2002, diClemente and Belville 2010) .
Physiology and pathophysiology of AMH in males
The changes of AMH expression follow the development of the male reproductive system, first of all changes in the activity of hypothalamo-pituitary-gonadal (HPG) axis. They may be divided into four main stages: fetal and early postnatal period, childhood, puberty and adulthood (Grinspon and Rey 2010). Variations in AMH formation are well reflected by its blood levels.
Fetal and early postnatal period: As mentioned above, AMH is synthesized in Sertoli cells of fetal testes already in early stage of embryonal development. In this period hypothalamus already produces gonadoliberin, which stimulates secretion of pituitary gonadotropins -lutropin (LH) and follitropin (FSH). By action of LH on Leydig cells of fetal testes via present receptors relatively high amounts of testosterone are formed (as detected for instance in newborn´s circulation). That´s also the reason that AMH levels are almost independent on the phase of the menstrual cycle, and usually a single mesurement is sufficient. It is adva! ntageous for interpretation of the diagnosis and also from the economical point of view (Visser et al. 2006 ). As was demonstrated on a group of women with polycystic ovary syndrome (PCOS) who underwent in vitro fertilization (IVF), the effect of IVF on the base of AMH determination, as a percentage of successful pregnancy could be predicted with sensitivity 75.6 and specificity 77.3% (Visser et al. 2006) .
AMH as an early marker of ovarian function cessation: Hand in hand with the decrease of the number of primary and preantral follicles with age, the production of AMH declines along with its blood levels. Low AMH levels and also their rapid decrease in certain time period are a marker of the drop off of an ovarian function (Visser et al. 20066) . In women under hormonal anticonception the proper function of ovaries cannot be evaluated without interruption of hormone administration for a period of 2-3 cycles, what brings about difficulties in a daily practice. Determination of FSH, LH and steroid hormone levels need not provide, in contrast to AMH, a reliable information because of certain residual gonadal activity. AMH and PCOS: Besides its utilization in IVF, determination of AMH may serve as an additional marker in the diagnostics of polycystic ovary syndrome, where increased AMH levels reflect the severity of the disease. Positive correlation of serum AMH with the number of antral follicles was found also in patients with PCOS. An increased production of AMH induces a decrease of sensitivity to FSH at receptor level, necessary for the growth of follicles. It leads to an increase of the number of antral follicles on the detriment of their size: the number of small antral follicles 2-5 mm in size increases, restraining thus selection of the dominant follicle. Such a situation is clinically characterized by anovulation cycles, manifesting themselve as oligo-or amenorrhea (Visser et al. 2006 ). In addition AMH inhibits peripheral aromatase, leading to hyperandrogenemia, another typical feature of PCOS. As mentioned already, secretion of AMH and its serum levels! decrease with age. In patients with PCOS this decline was surprisingly less distinct, indicating a slowed-down ovarian ageing, which may be explained by suppression of growth and differentiation of primordial follicles by high levels of AMH (Visser et al. 2006 , Kaya et al. 2010 , Pellat et al. 2010 , Park et al. 2010a .
When investigating possible genetical causes of PCOS, the question arose whether described mutations of AMH encoding gene are related to the disease. A genotypic analysis, however, did not reveal association of AMH gene mutations with PCOS, though they may contribute to aggravation of some features of the disease (Sproul et al. 2010 , Kevenaar et al. 2008 .
Besides hyperandrogenemia caused by increase of free testosterone, a characterisitic attribute of PCOS is insulinoresistance, usually expressed as the HOMA index, replacing in current medical practice euglycemic clamp. The studies of association of AMH levels with insulinoresistance surprisingly did not prove an unequivocal correlation among the investigated parameters: whilst in non-obese PCOS pacients the HOMA values as expected correlated positively with AMH levels, (Nardo et al. 2009 ), another study including also obese women (Chen et al. 2008) reported contradictory results: AMH correlated negatively with HOMA-index and also with BMI. It points to importance of obesity as one of the factors tightly bound with AMH regulation. A negative correlation between AMH and HOMA has been also found in healthy women without PCOS (Park et al. 2010b) . In this connection we should emphasize importance of sex hormone-binding (SHBG) determination, as an excellent! laboratory marker for PCOS, thanks to its involvement in endocrine regulations, first of all in gonadal and insular axes. It is well known that androgens suppress hepatal SHBG production, while estrogens increase it. Another SHBG feature is its negative association with insulinemia. A result of lowered SHBG levels is an increase of free androgens, which invoke further decrese of SHBG (Hampl and Stárka 1996) . SHBG is thus one of the connecting links in PCOS pathophysiology and obesity and it would be interesting to follow up relation of this protein to AMH.
AMH as a tumor marker
Serum AMH is a good marker of tumors originating from granulosa cells. Along with inhibin its determination was successfully tested as a marker of early diagnosis and response to the treatment. AMH appeared to be more specific, while sensitivity of both hormones was comparable (Geerts et al. 2009, La Marca and Volpe 2007) . The values of AMH in these patients correlated well with the size of the tumor (Chang et al. 2009 ). AMH may be used also for the follow up of gonadal function in reproduction in subjects who underwent therapy possessing undesired side effects on gonads (oncological therapy, immunosuppression) As an example we may bring in the study on females, who underwent in childhood a chemotherapy for Hodgkin lymphoma, in which lowered AMH levels reflected well a decreased ovarian reserve (vanBeek et al. 2007) . Recent research brought evidence that AMH determination may serve as a tool for diagnosis of some other neoplasia, as for instatn! ce a prostate cancer and could be used for detection of tumor recurrence The results however were not definite (Eldar-Geva et al. 2010) .
The levels of AMH in serum and the methods for its determination
Serum AMH levels are in the literature usually given in mass units (ng/ml or μg/l), which are used also in this article, though according to a good laboratory practice, more accurate is usage of S.I. units (pmol/l). The respective converting factor is [pmol/l] = 7.14 x [ng/ml]. In the Table 1 the medians and standard deviations of physiological levels are provided for women in a fertile age and in men and boys as reported in the literature. Out of many reports we show the extract of the data from representative reviews from 2004 (Laven et al. 2004 , La Marca et al. 2009 , Knauff et al. 2009 , Fréour et al. 2007 Table 1 are medians of these values.
As mentioned already, AMH levels in healthy women decline continually with age reaching non-measurable values after menopause. They are higher in women with PCOS and, on the other hand, very low in women with an ovarian failure. More detailed data on AMH according to the age and at various pathological situations in females may be found in the cited reviews (Laven et al. 2004 , La Marca et al. 2009 , Knauff et al. 2009 ), in boys and men in (Grinspon and Rey 2010 , Rey et al. 2009 ).
Since the end of nighties the immunological kits are available for AMH determination in body fluids (serum, plasma and also a follicular fluid). They usually apply sandwich systems with two specific antibodies to AMH: the first bound to a solid phase (in most instances the tube walls or titration wells), and the second labeled with biotin, to which the streptavidin-labeled enzyme is bound (usually horse-radish peroxidase). After addition of the substrate (a chromogenic conjugate which affords a a coloured product after cleavage by the enzyme) its absorbance is measured. The inserted streptavidin-biotin system increases the specificity and sensitivity of the method, which amounts approximately 1 ng/ml.
Conclusion
In advanced countries the determination of AMH belongs to a standard constituent of laboratory examination of the above mentioned states. The aim of this minireview is to inform the clinicians and scientists about the wide possibilities of utilization of AMH determination.
Last but not least an economical advantage of AMH determination over more expensive investigations used at IVF should be mentioned here, and also its contribution to early and targeted diagnosis of a number of disorders. One of the reason of this paper is to support the listing of AMH determination to the laboratory tests reimbursed by health insurance companies.
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